Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
Concurrent or sequential chemoradiotherapy has been recommended as the standard treatment for
locally advanced and unresectable non-small cell lung cancer (NSCLC). However, its efficacy
remains to be improved. PD-1/PD-L1 inhibitors have been proven to be effective for late-stage
NSCLC, and anti-angiogenesis agents have also been used for the first-line treatment of
advanced or metastatic NSCLC. Therefore, we designed this single-arm clinical trial, which
aims to investigate the safety and feasibility of sintilimab combined with anlotinib therapy
for patients with initially unresectable stage II-III NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Xinda Biopharmaceutical Group